Puma Biotechnology Inc. (PBYI)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XBER 
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
Puma Biotechnology Q4 earnings top estimates with 28% revenue jump, but weak 2026 outlook sparks 14% after-hours plunge.
Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript
Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates
Puma Biotech (PBYI) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.43 per share a year ago.
Puma Biotechnology: Step By Step In Making A Transition
Puma Biotechnology has been in something of a stasis for years, selling one drug with no new approvals while developing alisertib. The cash position remains strong enough to carry them through key readouts of the ALISCA trials. Two interim readouts guided in 1H 2026 will inform what is next for PBYI, and I think this has a lot of promise.
Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates
Puma Biotech (PBYI) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.45 per share a year ago.
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Puma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out?
Puma Biotech (PBYI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues
Puma Biotechnology tops second-quarter earnings and revenue estimates as rising Nerlynx sales drive growth.
Puma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call Transcript
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alan H. Auerbach - Founder, Chairman, President, CEO & Secretary Heather Blaber - Corporate Participant Mariann Ohanesian - Senior Director of Investor Relations Maximo F.
Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates
Puma Biotech (PBYI) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.05 per share a year ago.
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Puma Biotech (PBYI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
